A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer

Annals of Oncology

Volumn 11, Issue 7, 2000, Pages 829-835

  Sorensen, M ^a   Jensen, P B ^a   Herrstedt, J ^b   Hirsch, F R ^a   Hansen, H H ^a  

^a FINSEN LABORATORY   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

Cisplatin; Combination chemotherapy; Phase I; Phase II; Small cell lung cancer; Topotecan

Indexed keywords

CARBOPLATIN; CISPLATIN; TENIPOSIDE; TOPOTECAN; VINCRISTINE;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; LUNG SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033816778     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008393512479     Document Type: Article

References (23)

1. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880)
2. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies
3. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
4. Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication
5. Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks
6. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group
7. Phase II study of topotecan in patients with extensive-stage small-cell carcinomat of the lung: An Eastern Cooperative Oncology Group trial
8. Combination regimens with topotecan in animal tumor models
9. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines
10. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: A cancer and leukemia group study
11. Treatment-related fatal sepsis from topotecan-cisplatin and topotecan-paclitaxel
12. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence
13. Randomized trial in small cell lung cancer comparing the combination of cisplatin and carboplatin with carboplatin alone in combination chemotherapy
14. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells
15. Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule dependent process
16. Development of a stable camptothecin-resistant subline of p388 leukemia with reduced topoisomerase I content
17. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines
18. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan
19. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
20. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma
21. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
22. Effect of specific enzyme inhibitors on replication, total genome DNA repair and on gene-specific DNA repair after UV irradiation in CHO cells
23. Potentiation of cisplatin cytotoxicity by 9-aminocamptothecin